Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Regeneron announces FDA acceptance of BLA for linvoseltamab
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - REGN
NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors
This was the stock's second consecutive day of losses.
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
Regeneron Pharmaceuticals REGN +0.75% Get Free Report has outperformed the market over the past 20 years by 17.78% on an annualized basis producing an average annual return of 26.11%. Currently, ...
Hosted on MSN5d
Leerink Partners Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Market Perform to Outperform. Analyst Price Forecast Suggests 42.56% ...
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Is Regeneron Pharmaceuticals (REGN) Among the Best Depressed Stocks to Invest in Now?
We recently published a list of 12 Best Depressed Stocks to Invest in Now. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best ...
abc2719d
Robbins LLP Reminds REGN Shareholders to Seek Counsel for the Regeneron Pharmaceuticals, Inc. Class Action
Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others. For more information ...
Morningstar20d
Shareholders that lost money on Regeneron Pharmaceuticals, Inc.(REGN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely ...
abc2721d
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
According to the Complaint, the Company made false and misleading statements to the market. Regeneron paid credit card fees to distributors on the condition that those distributors did not charge ...
Insider Monkey23d
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
Cramer discussed how Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) keeps getting undermined despite the company’s rich pipeline and its strength in drug development. “How about Regeneron?